Pharmaceuticals news and pharmaceuticals widget

Israeli stocks were mixed on a volatile Monday, with Israel Chemicals down and Teva and Nice higher among the blue chips and tech hurt by Retalix and helped by Alvarion.

November is National Alzheimer's Awareness Month. In its honor, The Alzheimer Spouse website -www.thealzheimerspouse.com, - the only website on the Internet that deals exclusively with the unique issu... [WebWire - Monday, november 17, 2008]

Eli Lilly and Co. has licensed the U.S. commercialization rights for the active ingredient in its flagship erectile-dysfunction drug to United Therapeutics Corp. for uses as a high-blood-pressure treatment. But shares of the biotechnology concern slumped 31% premarket to $62.50, as United Therapeutics is buying the rights for $150 million. It has also agreed to sell $150 million in stock to Lilly. United Therapeutics' market value as of Friday was about $2.3 billion.

NEW YORK (MarketWatch) -- Eli Lilly and Co. said Monday that it has entered a license and supply agreement with United Therapeutics Corp. for U.S. commercialization rights for the pulmonary arterial hypertension indication of tadalafil. United Therapeutics will pay $150 million up front to Lilly for exclusive rights to commercialize tadalafil for PAH in the U.S. and for a manufacturing and supply arrangement. Lilly will also buy $150 million of United Therapeutics' common stock.

The Harley Medical Group, the UK's largest cosmetic surgery provider, has seen a dramatic five year rise in patients undergoing body corrective surgery to cope with the after effects of extreme post o... [WebWire - Monday, november 17, 2008]

SAN FRANCISCO (MarketWatch) -- Fitch Ratings said Monday it lowered the ratings outlook for Merck & Co. to negative from stable because top-selling drugs will lose patent protection over the next few years. Fitch has a AA- rating on Merck. About $6.93 billion in debt is affected by the ratings. "Fitch's outlook revision reflects an estimate of flat- to slightly declining revenues over the long term, as potential commercialization of the R&D pipeline will not fully offset declines due to the maturing drug product portfolio, with the worst effect on revenues in 2010, and lessened impacts in 2012 and 2013," the ratings agency said in a statement.

Billionaire investor Carl Icahn and his affiliates on Friday reported new stakes of 800,000 shares of Citigroup Inc. (C), 1.6 million shares of Advanced Micro Devices (AMD), and 461,128 shares of the Take-Two Interactive software Inc. (TTWO) acquired during the third quarter.

Photocure presented positive interim data at the six-month follow up stage of its phase I/II clinical feasibility study with Cevira? at the EUROGIN 2008 international conference. Cevira? is ...

The only known genetic risk factor for Alzheimer?s disease slows down the brain?s ability to export a toxic protein known as amyloid-beta that is central to the damage the disease causes, scientists ...

In response to increased demand for GMP peptide production, AnaSpec has established a new facility dedicated to GMP manufacturing. Located adjacent to its current San Jose, California-based ...